Case Report: the Comorbidity of Pregabalin-Use Disorder and Post-Traumatic Stress Disorder: Clinical and Pharmacological Issues

Galliot, Gaël; Ponté, Camille; Schmitt, Laurent; Hakimi, Yann; Sergent, Sami; Lapeyre‐Mestre, Maryse; Salles, Jean-Paul

doi:10.1007/s11469-020-00347-4

Cited by 2 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Health damages due to gabapentinoid abuse are to balance with their clinical efficacy. Precisely, after a growing enthusiasm for the multiform therapeutic virtues claimed by various promoters of this drug, a growing number of publications highlight the insufficient or unproven effectiveness of pregabalin in neuropathic pain and fibromyalgia ( 65 ), as well as in the management of substance use disorders ( 66 , 67 ) or long-term beneficial impact in post-traumatic stress disorder ( 68 ). Finally, recent observations from population-based studies, and animal models, have demonstrated that association of gabapentinoids and opioids (analgesics, maintenance drugs, or illicit opioids) significantly increase the risk of opioid death, with the reversibility of tolerance for opioid respiratory depression ( 36 – 38 , 40 ).…”

Section: Discussionmentioning

confidence: 99%

“…A hospitalization could be proposed if experiencing withdrawal difficulties or existing substance use disorder or psychiatric co-morbidities. The absence of a substance use transfer at the time of discontinuation should be monitored ( 68 ). To improve the knowledge on the evaluation of drugs in real life, at any time of management, to report any adverse event, including those related to substance use disorders, to the territorial vigilance systems.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction: Gabapentinoid drugs (gabapentin and pregabalin) are widely used worldwide for epileptic and pain disorders. First signals of gabapentinoid abuse occurred in the last decade. This study aims to describe clinical characteristics of gabapentinoid use related disorders and health consequences in France.Materials and Methods: We designed a multisource investigation reviewing data reported to the French Addictovigilance Network (FAN) with pregabalin and gabapentin from 2010 to 2019. Information was obtained through the analysis of Spontaneous Reports (SRs) notified by health professionals and the pharmacoepidemiological surveys OSIAP (suspicious prescriptions forms indicators of potential abuse), OPPIDUM (observation of illicit drugs and misuse of psychotropic medications), DRAMES (death related to prescription drugs and other substances), and DTA (toxic deaths due to analgesics).Results: Over 2010–2019 period, were collected: (i) 265 SRs (258 pregabalin; 7 gabapentin); (ii) 816 forged prescription forms (805 pregabalin, 10 gabapentin, 1 involving both drugs); (iii) 145 cases of gabapentinoid use in people who use drugs (121 pregabalin; 24 gabapentin) and (iv) 31 cases of gabapentinoid-related deaths (25 pregabalin; 6 gabapentin). Risk factors of gabapentinoid abuse were opioid use disorders or psychiatric history, but cases of primary abuse in subjects without any substance abuse history were observed. Adverse outcomes concern almost exclusively pregabalin, with coma, dyspnea, convulsion, and conduction disorders. Treatment demands increased from 10.6% in 2018 to 23.1% in 2019, with pregabalin cited as the first substance leading to addictological care in the 2019 OPPIDUM survey. Gabapentinoid-related deaths increased over time. Pregabalin has become the first drug mentioned in forged prescriptions in 2019 (23.8% of OSIAP), while it ranked at the 15th position in 2017 (2.6%).Discussion: This study shows the importance of addictovigilance monitoring for gabapentinoids. Addictovigilance data helped to make visible the gabapentinoid-abuse related health harms (hospitalization for serious neurologic, psychiatric or cardiac effects, requests for addictological support and deaths) and to confirm the intrinsic abuse potential of pregabalin. These data highlight new points of vigilance considering observed primary abuse. At this point in France, the risk of abuse and related complications is very apparent with pregabalin. Still, it is identical to that observed elsewhere with gabapentin.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“Just give me pregabalin, doctor”: pregabalin use disorder in two undocumented migrants from North Africa

Cunha,

Corvacho,

França

2023

Discov Psychol

View full text Add to dashboard Cite

Introduction Pregabalin is a widely prescribed medication for various medical conditions, including neuropathic pain and anxiety disorders. Recently, several studies have shown an increase in the recreational use of pregabalin, particularly among vulnerable populations, such as the migrant population. Methods The authors aim to present two case reports of pregabalin use disorder observed among migrants residing in a temporary detention center for undocumented migrants in Portugal, and to conduct a non-systematic review of the literature on the potential abuse of pregabalin. Results A growing body of research suggests an increasing global trend toward the inappropriate use linked with gabapentinoid medications, particularly pregabalin. The occurrence of euphoria, sedation, and dissociation at higher doses appears to be related to its abuse potential. Studies show that pregabalin abuse occurs particularly in patients with substance use disorders and in vulnerable populations such as migrants. Conclusion The migrant population appears to be particularly vulnerable to pregabalin abuse. Healthcare professionals should be aware of this emerging problem, especially if they work directly with this population. Prescribing should be done with caution, and when suspected, screening for abuse should be conducted.

show abstract

Case Report: the Comorbidity of Pregabalin-Use Disorder and Post-Traumatic Stress Disorder: Clinical and Pharmacological Issues

Cited by 2 publications

References 41 publications

Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance

Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance

“Just give me pregabalin, doctor”: pregabalin use disorder in two undocumented migrants from North Africa

Contact Info

Product

Resources

About